Antibody Treatment for HIV
SEEK, a privately-owned UK drug discovery group, announces that pre-clinical results on its HIV immunotherapy have been published in the peer-reviewed journal Virology Journal.
SEEK’s HIV immunotherapy triggers the immune system’s cellular and antibody responses to selectively identify and kill HIV infected cells. The most exciting aspect of this therapy is that it directs the immune system towards short highly conserved regions of proteins produced by most circulating HIV strains. The triggered immune responses are highly effective both independently and in combination.
This opens up developing the antibody response into a monoclonal based therapy for treating HIV.
Monoclonal antibodies have revolutionised the treatment of cancer by improving outcomes and survival. In HIV/AIDS there is new interest in these products, as shown by the recent work of Duke University (USA) in developing a monoclonal antibody that prevents the virus from infecting cells. A monoclonal antibody capable of killing HIV-infected cells (potentially curative effect) would represent a radical new development in HIV therapy, which to this day relies on slowing down the virus rate of growth rather than in killing the cells that harbour it.
By targeting a HIV component that is found only in infected cells and never in healthy cells, such monoclonal antibody therapy offers the potential of high specificity, reduced frequency of administration and minimal side-effects. This would represent a significant improvement over current anti-HIV drugs which require daily treatment and are associated with significant side effects.
Commenting on today’s announcement, Gregory Stoloff, CEO of SEEK Group said: ‘It is very exciting to be at the forefront of this new approach which opens up HIV therapy to established and available antibody technology.’
The manuscript: Olga Pleguezuelos, Gregory A Stoloff and Wilson Caparros-Wanderley, ‘Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation’, Virology Journal 2013, 10:107, can be found at the following URL: http://www.virologyj.com/content/10/1/107
In July 2011, SEEK announced the results of a Phase Ib/II study in humans which demonstrated that HIV immunotherapy showed a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single administration.
– ENDS –
For more information about SEEK please contact:
Gregory Stoloff, CEO, SEEK – Tel +44 (0)20 7153 6570
M:Communications Mary Clark / Amber Bielecka / Hollie Vile
Tel +44 (0)20 7920 2330 – Email: email@example.com
Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and funded, with headquarters in London, UK. Using a pioneering scientific and commercially-driven approach, SEEK aims to create breakthrough medicines which address major diseases in order to radically improve human health. SEEK’s strategy is to take promising molecules through the challenging stages of discovery to late-stage human proof-of-principle and then to seek partners to take the molecules through the final stages of development and ultimately commercialisation.
Additional information about SEEK and infirst HEALTHCARE is available on the Company’s website located at www.seekacure.com
infirst HEALTHCARE is a new consumer healthcare company focused on improving well established drugs with IP protected solutions for the OTC/Primary care market which can be launched within 12-36 months. infirst HEALTHCARE is a spin-out from SEEK, a UK privately-owned drug discovery group which uses its intellectual property to create breakthrough medicines addressing major diseases, bringing radical improvements to human health.